Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Lasers in Medical Science
Published in: Lasers in Medical Science 2/2022

01-03-2022 | Cutaneous Amyloidosis | Review Article

The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review

Authors: Najmeh Ahramiyanpour, Zahra Akbari, Mohammad Sharifi Sarasyabi, Mahin Aflatoonian, Nasrin Saki, Mohammad Shafie’ei

Published in: Lasers in Medical Science | Issue 2/2022

Login to get access

Abstract

With the investigation of the efficacy of laser therapy in primary localized amyloidosis(PLCA) only recently starting to materialize, we aimed to review the currently available studies of laser therapy in the management of the disease. We searched PubMed, Scopus, Embase, Web of Science, Cochrane, and ProQuest online databases with a specified search strategy, assessed the quality of each study, and then extracted the eligible data. Five RCTs(randomized controlled trials), one non-randomized controlled trial, three case series, and nine case reports(18 in total) were included. Overall, carbon dioxide (CO2), neodymium-doped:yttrium aluminum garnet (Nd:YAG), pulsed dye (PDL), Er (Erbium):YAG, and yttrium/erbium fiber were the studied lasers. One hundred fifty-five cases in total underwent laser therapy, with CO2 being the most frequent laser. Almost all studies demonstrated significantly desirable outcomes, while only mild and transient side effects were noted. Even though the studies’ results were significant, we noticed that implementing a consistent methodology and a standardized objective assessment method was missing. Therefore, we recommend that future studies be conducted with less heterogeneous data for a more definite conclusion.
Literature
1.
Borowicz J, Gillespie M, Miller R (2011) Cutaneous amyloidosis. Skinmed 9(2):96–100 (quiz 1)PubMed
2.
Mehrotra K, Dewan R, Kumar JV, Dewan A (2017) Primary cutaneous amyloidosis: a clinical, histopathological and immunofluorescence study. J Clin Diagn Res 11(8):Wc01-wc5PubMedPubMedCentral
3.
Sarkany RPE, Breathnach SM, Morris AAM, Weismann K, Flynn PD. Metabolic and nutritional disorders. Rook’s Textbook of Dermatology. 2010:1–103.
4.
Chiti F, Dobson CM (2017) Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem 86:27–68CrossRef
5.
Li WM (1990) Histopathology of primary cutaneous amyloidoses and systemic amyloidosis. Clin Dermatol 8(2):30–35CrossRef
6.
Terushkin V, Boyd KP, Patel RR, McLellan B (2013) Primary localized cutaneous amyloidosis. Dermatol Online J 19(12):20711CrossRef
7.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology: Elsevier; 2017.
8.
Ollague W, Ollague J, Ferretti H (1990) Epidemiology of primary cutaneous amyloidoses in South America. Clin Dermatol 8(2):25–29CrossRef
9.
Tan T (1990) Epidemiology of primary cutaneous amyloidoses in southeast Asia. Clin Dermatol 8(2):20–24CrossRef
10.
Konopinski JC, Seyfer SJ, Robbins KL, Hsu S (2013) A case of nodular cutaneous amyloidosis and review of the literature. Dermatol Online J 19(4):10CrossRef
11.
Kaltoft B, Schmidt G, Lauritzen AF, Gimsing P (2013) Primary localised cutaneous amyloidosis–a systematic review. Dan Med J 60(11):A4727PubMed
12.
Moon AO, Calamia KT, Walsh JS (2003) Nodular amyloidosis: review and long-term follow-up of 16 cases. Arch Dermatol 139(9):1157–1159CrossRef
13.
Fang S, Shen X, Chen AJ, Li S, Shan K (2015) Health-related quality of life in patients with primary cutaneous amyloidosis. PLoS One. 10(3):e0120623CrossRef
14.
Saki N, Ahramiyanpour N, Heiran A, Alipour S, Parvizi MM (2020) Efficacy of topical dimethyl sulfoxide (DMSO) 50% solution vs tretinoin 0.5% cream in treatment of patients with primary macular amyloidosis: a split-side single-blinded randomized clinical trial. Dermatologic Therapy 33(3):e13305CrossRef
15.
Weidner T, Illing T, Elsner P (2017) Primary localized cutaneous amyloidosis: a systematic treatment review. Am J Clin Dermatol 18(5):629–642CrossRef
16.
Tanzi EL, Lupton JR, Alster TS (2003) Lasers in dermatology: four decades of progress. J Am Acad Dermatol. 49(1):1–31 (quiz -4)CrossRef
17.
Al Yahya RS (2016) Treatment of primary cutaneous amyloidosis with laser: a review of the literature. Lasers Med Sci 31(5):1027–1035CrossRef
18.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 6(7):e1000097CrossRef
19.
Ostovari N, Mohtasham N, Oadras MS, Malekzad F (2008) 532-nm and 1064-nm Q-switched Nd:YAG laser therapy for reduction of pigmentation in macular amyloidosis patches. J Eur Acad Dermatol Venereol 22(4):442–446CrossRef
20.
Barsky M, Buka RL (2014) Pulsed dye laser for the treatment of macular amyloidosis: a case report. Cutis 93(4):189–192PubMed
21.
Khurana N, Urman C (2016) The efficacy of Q-switched ND:YAG 1064 nm laser in recalcitrant macular amyloidosis: a case report. J Drugs Dermatol 15(11):1456–1458PubMed
22.
Nilforoushzadeh MA, Zolghadr S, Heidari-Kharaji M, Alavi S, Mahmoudbeyk M (2020) A comparative study of the efficacy of fractional neodymium-doped yttrium aluminum garnet (Nd:YAG) laser therapy alone and in combination with erbium:YAG laser therapy: tracing and objective measurement of melanin index in macular amyloidosis. Lasers Med Sci 35(5):1171–1177CrossRef
23.
Nahidi Y, Delghandi SR, Kiafar B, Saki A (2021) The therapeutic effects of 1540-nm non-ablative fractional erbium laser on macular amyloidosis: a randomized clinical trial. J Dermatolog Treat 32(3):340–344CrossRef
24.
Sobhi RM, Sharaoui I, El Nabarawy EA, Esmail RSE, Hegazy RA, Aref DHF (2018) Comparative study of fractional CO2 laser and fractional CO2 laser-assisted drug delivery of topical steroid and topical vitamin C in macular amyloidosis. Lasers Med Sci 33(4):909–916CrossRef
25.
Anitha B, Mysore V (2012) Lichen amyloidosis: novel treatment with fractional ablative 2,940 nm erbium: YAG laser treatment. J Cutan Aesthet Surg 5(2):141–143CrossRef
26.
Korbi M, Akkari H, Soua Y, Mohamed M, Youssef M, Belhajdali H et al (2019) Lichen amyloidosis successfully treated with fractional ablative laser CO2: a new alternative therapeutic. J Cosmet Laser Ther 21(1):1–3CrossRef
27.
Liu HT (2000) Treatment of lichen amyloidosis (LA) and disseminated superficial porokeratosis (DSP) with frequency-doubled Q-switched Nd:YAG laser. Dermatol Surg 26(10):958–962CrossRef
28.
Norisugi O, Yamakoshi T, Shimizu T (2014) Successful treatment of lichen amyloidosis using a CO2 surgical laser. Dermatol Ther 27(2):71–73CrossRef
29.
Panchaprateep R, Tusgate S, Munavalli GS, Noppakun N (2015) Fractional 1,550nm ytterbium/erbium fiber laser in the treatment of lichen amyloidosis: clinical and histological study. Lasers Surg Med 47(3):222–230CrossRef
30.
Esmat SM, Fawzi MM, Gawdat HI, Ali HS, Sayed SS (2015) Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: a randomized clinical trial. Lasers Surg Med 47(5):388–395CrossRef
31.
Fawzi MMT, Gawdat HI, Mahmoud SB, El-Hawary MS, Rashed LA, Esmat SM (2021) Fractional carbon dioxide laser is effective in amelioration of pruritus in primary cutaneous amyloidosis: a clinical and biochemical study. Lasers Surg Med 53(4):482–487CrossRef
32.
Fawzy MM, Kamel MM, El Maadawi Z, Abdel Hady R, Osman MA. Fractional erbium-doped yttrium aluminum garnet laser in the treatment of primary cutaneous amyloidosis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]. 2021.
33.
Alster TS, Manaloto RMP (1999) Nodular amyloidosis treated with a pulsed dye laser. Dermatol Surg 25(2):133–135CrossRef
34.
Hamzavi I, Lui H (1999) Excess tissue friability during CO2 laser vaporization of nodular amyloidosis. Dermatol Surg 25(9):726–728CrossRef
35.
Lesiak A, Rakowski A, Brzezinska A, Rogowski-Tylman M, Kolano P, Sysa-Jedrzejowska A et al (2012) Effective treatment of nodular amyloidosis with carbon dioxide laser. J Cutan Med Surg 16(5):372–374CrossRef
36.
Truhan AP, Garden JM, Roenigk HH Jr (1986) Nodular primary localized cutaneous amyloidosis: immunohistochemical evaluation and treatment with the carbon dioxide laser. J Am Acad Dermatol 14(6):1058–1062CrossRef
Metadata
Title
The therapeutic role of lasers in primary localized cutaneous amyloidosis: a systematic review
Authors
Najmeh Ahramiyanpour
Zahra Akbari
Mohammad Sharifi Sarasyabi
Mahin Aflatoonian
Nasrin Saki
Mohammad Shafie’ei
Publication date
01-03-2022
Publisher
Springer London
Published in
Lasers in Medical Science / Issue 2/2022
Print ISSN: 0268-8921
Electronic ISSN: 1435-604X
DOI
https://doi.org/10.1007/s10103-021-03429-4

Other articles of this Issue 2/2022

Lasers in Medical Science 2/2022 Go to the issue

Original Article

Efficacy of fractional laser, radiofrequency and IPL rejuvenation of periorbital region

Review Article

Efficacy of near infrared dental lasers on dentinal hypersensitivity: a meta-analysis of randomized controlled clinical trials

Review Article

Photobiomodulation impacts the levels of inflammatory mediators during orthodontic tooth movement? A systematic review with meta-analysis

Original Article

Comparison of picosecond versus nanosecond Nd:YAG lasers for the removal of cosmetic tattoos in an animal model

Original Article

Photobiomodulation enhances facial nerve regeneration via activation of PI3K/Akt signaling pathway–mediated antioxidant response

Original Article

What else than eyes need special protectors during laser hair reduction sessions?